or Try an Advanced Search...

    Neuropathic Pain Stocks List

    Symbol Grade Name % Change
    XENE D Xenon Pharmaceuticals Inc. 1.17
    ASRT D Assertio Therapeutics, Inc. 1.65
    NKTR F Nektar Therapeutics 1.00
    CHRO F Chromocell Therapeutics Corporation 1.94
    RVNC F Revance Therapeutics, Inc. 1.05
    BIIB F Biogen Idec Inc. 1.29
    BLRX F BioLineRx Ltd. -40.70
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Pain Biopharmaceutical Biotechnology Acute Pain Analgesics Chemical Compounds Clinical Development Drugs Erythromelalgia Immunology Migraine Opioids Organic Compounds Pharmaceutical Pharmacology Postherpetic Neuralgia Acne Acute Myeloid Leukemia Alipogene Tiparvovec Alzheimer's Disease

    Related ETFs - A few ETFs which own one or more of the above listed Neuropathic Pain stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.6
    MNTL D Tema Neuroscience and Mental Health ETF 5.82
    PBE D PowerShares Dynamic Biotech & Genome 4.21
    BBH D Market Vectors Biotech ETF 3.86
    IBRN C iShares Neuroscience and Healthcare ETF 3.86
    View all Neuropathic Pain ETFs...
    Compare ETFs
    Compare BBH to IBRN Compare BIS to IBRN Compare PBE to IBRN

        Neuropathic Pain Stocks Recent News

        Date Stock Title
        Nov 21 BLRX BioLineRx inks licensing deal, share purchase agreement
        Nov 21 BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
        Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
        Nov 20 BLRX BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
        Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 RVNC Revance Therapeutics gains as Crown Labs further extends tender offer
        Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
        Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
        Nov 18 NKTR Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
        Nov 18 BIIB Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
        Nov 18 BIIB Needham downgrades Biogen on slow growth of Alzheimer's drug
        Nov 18 BIIB Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
        Nov 18 BIIB Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
        Nov 18 BIIB Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
        Nov 15 BIIB Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Pain Biopharmaceutical Biotechnology Acute Pain Analgesics Chemical Compounds Clinical Development Drugs Erythromelalgia Immunology Migraine Opioids Organic Compounds Pharmaceutical Pharmacology Postherpetic Neuralgia Acne Acute Myeloid Leukemia Alipogene Tiparvovec Alzheimer's Disease
        Neuropathic Pain

        Neuropathic pain is a type of chronic pain that is caused by damage or disease affecting the somatosensory nervous system. It is often described as a shooting, burning, or tingling sensation. Neuropathic pain can be caused by a variety of conditions, including diabetes, multiple sclerosis, shingles, and spinal cord injury.

        Browse All Tags